Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies

https://doi.org/10.1016/0165-5728(93)90157-TGet rights and content

Abstract

Chronic relapsing experimental allergic encephalomyelitis (CREAE) was induced in Biozzi AB/H (H-2dq1) mice by active sensitization with spinal cord antigens. A single i.p. injection of CD8-depleting (YTS169.4) monoclonal antibody (mAb) failed to affect the clinical course of CREAE when administered prior to and during the onset of both the initial clinical and subsequent relapse phase of the disease. By ccontrast similar treatment with both CD4-depleting (YTS191.1) or CD4-blocking/non-depleting (YTS177.9) mAb significantly inhibited disease progression. Treatment shortly before the anticipated onset of clinical EAE prevented the subsequent development of disease, although disease could be provoked following antigen-rechallenge. In contrast, treatment with these antibodies during post-acute remission phase mainly served to delay the incidence of relapse. This suggests that, unless tolerance can be re-induced, treatment of ongoing neuroimmunological disease will require ‘pulse’ therapy and thus potentiate the problems of long-term immunosuppesion. Despite the findings that CD4-specific antibodies can rapidly reverse overt clinical disease shortly after the onset of disease exacerbation, once neurological dysfunction becomes established anti-CD4 treatment fails to improve the animals clinically, possibly due to the inability to rapidly reverse established demyelination. Although this study does not exclude the potential central action of the injected mAb, the failure to significantly dissociate therapeutic benefit between mAb administered directly into the CNS and that given systemically suggests that a major action of these agents is probably by selectively removing T cells in the peripheral T cell pool.

References (56)

  • S.E. Alters et al.

    Mechanisms of anti-CD4 mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies

    J. Immunol.

    (1990)
  • E.C. Alvord et al.

    Experimental allergic encephalomyelitis: A useful model of multiple sclerosis

    (1984)
  • D. Baker et al.

    Mechanisms of immune-mediated demyelinating disease of the central nervous system

    Neurochem. Res.

    (1991)
  • D. Baker et al.

    Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent. Elucidation by the action of mitoxantrone

    Clin. Exp. Immunol.

    (1992)
  • D. Barnes et al.

    The longstanding MS lesion. A quantitative MRI and electron microscopic study

    Brain

    (1991)
  • R.J. Benjamin et al.

    Tolerance to rat monoclonal antibodies

    J. Exp. Med.

    (1986)
  • S.W. Brostoff et al.

    Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognized T helper cells

    J. Immunol.

    (1984)
  • A.M. Brown et al.

    Chronic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse

    Lab. Invest.

    (1982)
  • M. Brüggeman et al.

    Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies

    J. Exp. Med.

    (1987)
  • K. Burkhardt et al.

    An increase in the survival of murine H-2 mismatched cultured fetal pancreas allografts using depleting or nondepleting anti-CD4 monoclonal antibodies, and a further increase with cyclosporine

    Transplantation

    (1989)
  • N.L. Carteron et al.

    Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on deletion of L3T4+ cells

    J. Immunol.

    (1988)
  • S.P. Cobbold et al.

    Therapy with monoclonal antibodies by elimination of T cell subsets in vivo

    Nature

    (1984)
  • S.P. Cobbold et al.

    The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies

    Eur. J. Immunol.

    (1990)
  • D.P. Dialynas et al.

    Characterization of the murine T cell surface molecule designated L3T4 identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule

    J. Immunol.

    (1983)
  • R.B. Fritz et al.

    Major histocompatibility complex-linked control of the murine immune response to myelin basic protein

    J. Immunol.

    (1985)
  • D.A. Hafler et al.

    In vivo labelling of blood T cells: rapid traffic into the cerebrospinal fluid in multiple sclerosis

    Ann. Neurol.

    (1987)
  • J.O. Harris et al.

    Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

    Ann. Neurol.

    (1991)
  • C. Herzog et al.

    Anti-CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical course and circulating T cells

    J. Autoimmun.

    (1989)
  • Cited by (0)

    View full text